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Introduction
I read with interest the recent article by Osman et al. (2015)
in Reproductive Biomedicine Medicine Online and the ac-
companying editorial by Drobnis and Johnson (2015). I was
hoping for a progressive approach but, alas, despite further
conﬁrmatory studies since the last systematic review by Zini
and Sigman (2009), these authors seemed determined to draw
the same, well-worn conclusions.
Those of us working in this ﬁeld are equally keen to see
more well-designed, adequately powered studies with live
birth outcomes. We are also, however, too well aware of the
hurdles and time required to achieve these ideals. Having at-
tempted to secure funding for just such a study with El-Toukhy
and other colleagues in centres excelling in andrology, we all
know that this topic is not a priority for the Medical Re-
search Council or the National Institute for Health Re-
search. In the intervening time, until such data are available,
is it still best practice to provide men with only inadequate
semen testing knowing its limitations?
May I address a number of the speciﬁc, perceived short-
comings of sperm DNA damage testing?
Will the results change practice? Will testing add to
the information already provided when taking a
medical history?
Yes. Clearly, those men who have high levels of sperm DNA
damage would be more likely to achieve a pregnancy with in-
tracytoplasmic sperm injection (ICSI) than IVF because sperm
with DNA damage do not seem to produce adverse affects on
early ICSI outcomes. Why? This may be for a number of related
reasons associated with the ability of the oocyte to repair at
least some sperm DNA damage before ﬁrst cleavage. First,
unlike IVF, up to 30% of women having ICSI have no detect-
able problems. They may be fertile and their oocytes may have
more capacity to repair DNA damage even if the injected
sperm is of poor quality. This is supported by Meseguer et al.
(2011), who found that high-quality oocytes from donors offset
the negative effect of sperm DNA damage on pregnancy.
Second, in ICSI, the gametes are not subjected to pro-
longed culture so the sperm may have less damage than those
exposed to culture media overnight, as in IVF procedures. The
studies from Dumoulin et al. (2010) and Kleijkers et al. (2014)
show that, for IVF babies, the birth weight and 2-year growth
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markers can be markedly inﬂuenced by minor differences in
culture conditions. In contrast to IVF, ICSI sperm are in-
jected into the optimal environment of the ooplasm within
a few hours of ejaculation. This may protect them from
laboratory-induced damage and allow the oocyte to begin
repair earlier.
Third, it is well documented that sperm from up to 40%
of infertile men have high levels of reactive oxygen species
(ROS) (Aitken et al., 2012), and their antioxidant content is
also signiﬁcantly lower than fertile men (Lewis et al., 1995).
During the IVF process, oocytes can be exposed to oxidative
assault overnight from up to 0.5 million sperm releasing ROS.
This may well impair the oocyte’s functional capacity to repair
sperm DNA fragmentation (DNA-F) after fertilization and before
cleavage.
There are patients with normal semen parameters
and high DNA-F; does this mean all men should be
tested during work-up?
Again, the answer must be yes. All men with normozoospermic
semen proﬁles should be tested. Most clinicians agree on the
limitations of conventional semen analysis. We also know that
about 25% of couples are diagnosed with idiopathic infertil-
ity as a result of the limitations of current testing. Couples
with unexplained infertility perform less well after IVF than
couples with detectable causes of infertility, added to which
a signiﬁcant number of the male partners have high sperm
DNA damage (Oleszczuk et al., 2013; Simon et al., 2013) . Now
that we have found a test that can detect molecular anoma-
lies in sperm, why would we not use it as an adjunct to the
semen analysis? This is not just ‘an emotionally satisfying’ test
as suggested in the editorial. It is a more sensitive molecu-
lar test that looks at the paternal genome; the only sperm
parameter that affects offspring health.
Is DNA testing better than any previous
andrological test?
Yes. It is, however, being withheld from clinical use by ex-
cessively rigorous demands for evidence of quality. In most
reviews of this nature, there is a common style. All previous
inadequate andrological tests (except semen analysis) are
listed and dismissed within one sentence. Then, this one test
is expected to pass scrutiny at the highest level: Level 1 evi-
dence of quality from randomized controlled trials (RCTs),
before clinical use. This is in stark contrast to the approach
used for ICSI in 1995, when it became a routine publically
funded fertility treatment on a global scale without human
trials. A second example of a new fertility technology be-
coming routine before passing such stringent standards is the
use of time-lapse imaging. It has become a routine tool for
many clinics, despite limited and conﬂicting evidence or im-
proved assisted reproduction technique outcomes. Further,
a review (Glujovsky et al., 2012) of the quality of RCTs
between 2006 and 2011 in ﬁve leading human reproduction
journals pointed out that incomplete outcome data and in-
adequate allocation concealment led to bias in almost 50%
of them. Hence, to wait for a useful RCT in this area may not
be in patient’s best interest.
The current ‘gold standard’ semen analysis would not pass
a Level 1 evidence of quality at any level: whether based on
accuracy, reproducibility, diagnostic or prognostic useful-
ness. I dispute the authors’ comment on the sensitivity and
speciﬁcity of a semen analysis being useful. The values they
cited were for natural fertility not assisted conception, and
they were based on studies conducted between 1997 and 2001.
Reviews by Leﬁèvre et al. (2007) and the British Fertility
Society andrology guidelines (Tomlinson et al., 2013) high-
light the limitations of the semen analysis. This is not sur-
prising, as only 1% of sperm reach the site of fertilisation in
vivo, so to expect an analysis of an ejaculate’s gross param-
eters to give strong discriminatory information is also unre-
alistic. In its current form, a semen analysis should be
considered only as a means of identifying men whose chance
of achieving a natural pregnancy is reduced (Lewis et al.,
2013). Knowing this, however, suggests an additional test
needs to be implemented today.
Most existing studies evaluating the utility of DNA-F
testing for the diagnosis of infertility suffer from
multiple weaknesses as discussed recently in an
American Society for Reproductive Medicine
Practice Committee guideline, 2013
The American Society of Reproductive Medicine (ASRM) cited
here, is, in my opinion, a negatively biased and unbalanced
overview. It dismissed the ﬁndings of around 100 papers in
high-impact journals over the last 30 years as ‘insufﬁcient
evidence’ and turned the evidence from the range of differ-
ent sperm DNA tests measuring different aspects of DNA
damage into a weakness rather than accepting this as the
strength it is.
The level of precision that ASRM requires can never come
from one ‘male only’ test. Fertilization is a multi-factorial
process and a successful assisted reproduction technique
outcome depends on many other traits of sperm quality and
function, as well as the inﬂuences of the oocyte, uterine re-
ceptivity and maternal immune system competence. Finally,
the authors of the ASRM document, having begun by criticiz-
ing DNA testing as measuring different aspects of DNA damage
and, therefore, being non-uniform, then criticized DNA testing
for being non-speciﬁc by not providing ‘an indication of spe-
ciﬁc DNA sequences that may be affected’. As no one yet
knows what aspects of DNA damage at large, or of any spe-
ciﬁc sequences that are responsible for ‘male infertility’,
neither of these opposing criticisms is based on sound
science.
As a co-author of the European Society of Human Repro-
duction and Embryology guidelines (Barratt et al., 2011), I am
always surprised to see them cited in opposition to sperm DNA
testing. The paper was written as a broad scientiﬁc over-
view, as the title suggests ‘Sperm DNA: organization, pro-
tection and vulnerability: from basic science to clinical
applications – a position report.’ Its coverage of clinical testing
was far from exhaustive, citing only a few reviews and com-
posing less than 10% of the paper content. We ended with a
plea for further funding for fundamental male reproduc-
tion. That was 5 years ago and the plea remains unheeded.
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Again, I ask, should infertile couples be disadvantaged by re-
fusing to offer them these tests while we wait for further sup-
portive data that may take years to fund?
It will be important to compare the value of DNA-F
testing with other tests that could provide the
same information, for example, a combination of
semen analysis and reactive oxygen species
concentration
The advantage of sperm DNA testing is that it adds to our
current knowledge. No other tests provide the same infor-
mation. In a study of 1633 semen samples tested for 21 pa-
rameters, only seven of them showed any correlation between
sperm DNA (Cohen-Bacrie et al., 2009). If sperm DNA damage
correlated with a semen analysis, then DNA testing would be
unnecessary. In response to the authors’ comment about a
relationship with ROS, this is a difﬁcult parameter to measure
as it has a half-life of milliseconds. Much evidence already
shows that most sperm DNA damage is caused by oxidative
stress (reviewed by Aitken et al., 2012), so sperm DNA damage
is accepted as a robust end point of irreversible damage by
this process.
Beyond diagnosing male factor infertility, can we
use DNA-F testing to decide which interventions
will best treat our infertile couples? If so,
signiﬁcant cost and risk to the patient could be
minimized. The ideal study would recruit men with
positive and negative DNA-F tests, and randomly
assign them to different treatments: expectant
management versus intrauterine insemination
versus IVF versus IVF–ICSI
I agree. Intrauterine insemination (IUI) is no longer recom-
mended by the National Institute for Health and Care Excel-
lence, but a study of couples randomly allocated to IVF or ICSI
could be useful. I have proposed this type of study to clini-
cal colleagues on many occasions. It has always been met with
ethical disapproval, however. Some clinics objected as they
were averse to performing ICSI on couples with normal semen
as it was too invasive. Other clinics objected for the con-
verse reason; they used ICSI rather than IVF as the more suc-
cessful treatment for most patients. A further hurdle is that
couples are often self-funded and, when they are fully in-
formed of the details of such a study, they do not want to
jeopardise their chances of success by choosing a treatment
that they perceive as less successful.
In closing, I would highlight two new publications from Doug
Carrell’s group (Simon et al., 2014a, 2014b). These add further
support to the beneﬁts of sperm DNA testing and show the
strong affect of the paternal genome on fertilization and early
embryo quality giving us new possibilities to incorporate male
testing with time-lapse imaging.
We have two choices. We can allow this inertia to con-
tinue and our traditional tests to prevail, but that may prevent
an improvement in our success rates in the diagnosis and treat-
ment of male infertility. Alternatively, we can embrace
innovation in male fertility testing and see if success rates
improve. Which is greater: risk or beneﬁt? What is in the best
interest of the infertile couple?
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